Dr Kerstin Papenfuss, Deep Science Ventures, and Ben Holland, Antiverse, discuss how generative AI is helping advance antibody discovery. The therapeutic antibody, once ‘the next big thing,’ has matured into a cornerstone of modern medicine,… Read More
A new multi-target partnership aims meet unmet need by designing antibodies for G-protein coupled receptors (GPCRs). The collaboration will combine Antiverse’s generative AI antibody design expertise, including its proprietary machine-learning-generated ‘epitope-specific libraries’, with Nxera’s NxWave platform for GPCR target selection, validation and structural determination. Read More
Antiverse is an artificial intelligence (AI)-driven company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Murat Tunaboylu, Co-founder and CEO of Antiverse, speaks with Megan Thomas about how AI can advance therapeutic antibody design. Megan T: How is Antiverse using… Read More
DDW’s Megan Thomas spoke to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. This is part of a series of predictions based on different themes. Here, experts weigh in on the impact of artificial intelligence (AI), machine learning (ML) and automation in… Read More
Antiverse has successfully identified functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both displaying versatile binding profiles and nanomolar affinity. The company has raised $3 million in funding, which will enable in-house development of the antibodies showing the highest affinity blocking function. The antibodies were identified using Antiverse’s proprietary… Read More
